期刊文献+

磁共振弥散成像在急性脑梗死诊断治疗中的应用及其临床意义分析 被引量:11

下载PDF
导出
摘要 急性脑梗死是临床常见的脑血管疾病,具有较高的致残率及病死率,对患者的生活质量及生命安全均造成严重影响,因此对于急性脑梗死患者应进行早期诊断及及时治疗,进而改善患者预后[1,2]。由于脑梗死起病较急,常规磁共振成像(MRI)及CT检查虽能够明确脑梗死的部位、脑水肿程度、脑组织坏死大小等,对临床治疗具有一定的指导意义,但是在患者发病早期不能够发现病灶,且敏感度欠佳[3-5]。
作者 侯鹏春
出处 《中国药物与临床》 CAS 2020年第23期3914-3916,共3页 Chinese Remedies & Clinics
  • 相关文献

参考文献11

二级参考文献107

  • 1各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量:33041
  • 2Weber RA, Hui ES,JensenJH, et al. Diffusional kurtosis and diffusion tensor imaging reveal different time-sensitive stroke-induced microstructural changes[J]. Stroke,2015 ,46(2) :545-550.
  • 3AI-Ali F, EliasJ J, Tomsick TA, et al. Relative Influence of Capillary Index Score, Revascularization, and Time on Stroke Outcomes From the Interventional Management of Stroke m Trial[J] . Stroke,2015,46(6) :1590-1594.
  • 4Akamatsu H, Inoue A, Mitsudomi T, et al. Interstitial lung disease associated with gefitinib inJapanese patients with EGFR?mutated non-small-cell lung cancer: combined analysis of two Phase m trials (NEJ 002 and WJTOG 3405 )[J].JpnJ Clin Oncol, 2013, 43(6) :664-668.
  • 5Zhou C, W u YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation?positive non-small-cell lung cancer ( OPTIMAL, CTONG'f)802) : a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2011,12(8) :735-742.
  • 6Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC):a multicentre, open-label, randomised phase 3 trial[J]. Lancet Oncol, 2012,13(3) :239-246.
  • 7YangJC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase m study of afatinib or cisplatin/' pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations[J].J Clin Oncol, 2013, 31(27) :3342-3350.
  • 8Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX?Lung 6) : an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15 (2) :213-222.
  • 9Shi Y, AuJS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)[J].J Thorac Oncol, 2014, 9(2) : 154-162.
  • 10Janne PA, YangJC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancerj T]. N EnglJ Med, 2015,372(18) :1689-1699.

共引文献282

同被引文献97

引证文献11

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部